|
See related Stalevo information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Zuellig |
|
Contents |
Per 50/12.5/200 mg tab Levodopa 50 mg, carbidopa 12.5 mg, entacapone 200 mg. Per 100/25/200 mg tab Levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg. Per 150/37.5/200 mg tab Levodopa 150 mg, carbidopa 37.5 mg, entacapone 200 mg. Per 200/50/200 mg tab Levodopa 200 mg, carbidopa 50 mg, entacapone 200 mg |
|
Indications |
Parkinson's disease & end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Click to view Stalevo detailed prescribing infomation |
|
Dosage |
1 tab/dose administration. Max: 10 tab/day.
Click to view Stalevo detailed prescribing infomation |
|
Overdosage |
View Stalevo overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Concomitant use of MAOIs (discontinue use at least 2 wk prior to initiating therapy). Severe hepatic impairment. Narrow-angle glaucoma. Pheochromocytoma. History of neuroleptic malignant syndrome (NMS) &/or nontraumatic rhabdomyolysis.
Click to view Stalevo detailed prescribing infomation |
|
Special Precautions |
Not for drug-induced extrapyramidal reactions. Severe CV or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease, or history of PUD or convulsions. History of MI w/ residual atrial nodal or ventricular arrhythmias. Monitor patients for development of mental changes, depression w/ suicidal tendencies & serious antisocial behaviour. Past or current psychosis. Chronic wide-angle glaucoma. May induce orthostatic hypotension. May affect ability to drive or operate machinery. Abrupt dose reductions or w/drawal of levodopa in patients who are also receiving neuroleptics. Periodic eva luation of hepatic, haematopoietic, CV & renal function on extended therapy. Pregnancy & lactation.
Click to view Stalevo detailed prescribing infomation |
|
Adverse Drug Reactions |
Levodopa/Carbidopa: Dyskinesias including choreiform, dystonic & other involuntary movements, muscle twitching & blepharospasm, nausea, mental changes. Entacapone: GI symptoms, insomnia, hallucinations, confusion, paranoia, dyskinesia, aggravated parkinsonism, dizziness, dystonia, hyperkinesia, fatigue, increased sweating, fall.
View ADR Monitoring Form |
|
Drug Interactions |
Not to be used concurrently w/ entacapone. Antihypertensives, antidepressants, MAO-A inhibitors, TCA, desipramine, maprotiline & venlafaxine, rimiterol, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, α methyldopa, apomorphine & paroxetine. Dopamine receptor antagonists, phenytoin & papaverine, S warfarin, high-protein diet, Fe prep (take at least 2-3 hr apart).
View more drug interactions with Stalevo |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Stalevo storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Stalevo description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Stalevo mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Stalevo 50/12.5/200 mg film-coated tablet |
|
|
Stalevo 100/25/200 mg film-coated tablet |
|
Stalevo 100's |
 |
|
|
Stalevo 150/37.5/200 mg film-coated tablet |
|
Stalevo 100's |
 |
|
|
Stalevo 200/50/200 mg film-coated tablet |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Zuellig
|
|
|
|
